Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013:2013:476525.
doi: 10.1155/2013/476525. Epub 2013 Oct 21.

Topical nonsteroidal anti-inflammatory drugs for macular edema

Andrea Russo  1 , Ciro Costagliola, Luisa Delcassi, Francesco Parmeggiani, Mario R Romano, Roberto Dell'Omo, Francesco Semeraro
Affiliations
Review

Topical nonsteroidal anti-inflammatory drugs for macular edema

Andrea Russo et al. Mediators Inflamm. 2013.

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are nowadays widely used in ophthalmology to reduce eye inflammation, pain, and cystoid macular edema associated with cataract surgery. Recently, new topical NSAIDs have been approved for topical ophthalmic use, allowing for greater drug penetration into the vitreous. Hence, new therapeutic effects can be achieved, such as reduction of exudation secondary to age-related macular degeneration or diabetic maculopathy. We provide an updated review on the clinical use of NSAIDs for retinal diseases, with a focus on the potential future applications.

PubMed Disclaimer

References

    1. Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. International Journal of Inflammation. 2013;2013:8 pages.281981 - PMC - PubMed
    1. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Survey of Ophthalmology. 1992;36(4):259–284. - PubMed
    1. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. International Ophthalmology Clinics. 2002;42(1):1–11. - PubMed
    1. Flaxel C, Schain MB, Hamon SC, Francis PJ. Prospective randomized controlled trial of combination ranibizumab (lucentis) and bromfenac (xibrom) for neovascular age-related macular degeneration: a pilot study. Retina. 2012;32(3):417–423. - PubMed
    1. Gomi F, Sawa M, Tsujikawa M, Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina. 2012;32:1804–1810. - PubMed

MeSH terms

Substances

LinkOut - more resources